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Insights into mechanisms
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) 
and psoriatic arthritis (PsA) are all associated with a 
probably distinct immune-mediated pathogenesis that is 
central to the pathophysiology of each disease but ulti-
mately leads to a chronic inﬂ  ammatory response as a ﬁ  nal 
common pathway. Th  is fundamental inﬂ  ammatory  res-
ponse is characterised by an overproduction of pro  inﬂ  am-
matory cytokines, particularly TNF, IL-1 and IL-6 [1].
TNF is a dominant proinﬂ  ammatory cytokine in RA, 
AS and PsA. Th   e cytokine has both a direct eﬀ  ect and an 
indirect eﬀ  ect on the inﬂ  ammatory events in these condi-
tions [2-4]. TNF induces macrophages and other cells to 
secrete other proinﬂ  ammatory cytokines (for example, 
IL-1, IL-6, IL-8), leads to T-cell activation and induces 
endothelial cells to express both adhesion molecules that 
increase T-cell inﬁ  ltration and vascular growth factors 
that promote angiogenesis and keratinocyte proliferation. 
TNF is also involved in the diﬀ  erentiation and maturation 
of osteoclasts, the pivotal cells engaged in bone destruc-
tion in arthritis [5], and stimulates ﬁ  broblasts, osteoclasts 
and chondrocytes to release protein  ases, which destroy 
articular cartilage and bone [1,3,6,7].
Typical inﬂ  ammatory symptoms in RA include joint 
swelling and pain, systemic malaise and morning joint 
stiﬀ  ness. As RA progresses, continued inﬂ  ammation leads 
to permanent damage to the cartilage, bone, tendons and 
ligaments and, subsequently, to joint destruction and 
disability [1].
AS is primarily a disease of the axial skeleton that 
involves the sacroiliac joints and spine [8]. Inﬂ  ammatory 
back pain with stiﬀ  ness is the main clinical symptom [9]. 
Nonaxial involvement may include peripheral joint 
arthritis (most commonly of the knees), enthesitis and 
dactylitis [10,11]. Extra-articular manifestations are fairly 
common in AS patients [12-14] and can aﬀ  ect the eyes, 
gastrointestinal tract, lungs, heart and bones.
PsA is characterised by joint damage with associated 
pain and swelling. Th   e disorder is similar to RA but with 
less severe symptoms. Nail abnormalities, psoriatic skin 
lesions, enthesitis and dactylitis are common in PsA [15]. 
Nail psoriasis is associated with a higher prevalence of 
joint involvement and a more progressive form of the 
disease [16,17]. Th   e skin lesions usually manifest before 
arthritic symptoms [18].
Targeting underlying infl  ammation
Disease control diﬀ  ers among RA, AS and PsA. In AS, 
nonsteroidal anti-inﬂ   ammatory drugs can slow or 
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Rheumatoid arthritis (RA), ankylosing spondylitis (AS) 
and psoriatic arthritis (PsA) are immune-mediated 
conditions that share an infl  ammatory mechanism 
fuelled by excessive cytokines, particularly TNF. Control 
of infl  ammation and rapid suppression of cytokines 
are important in treating these diseases. With this 
understanding and the corresponding advent of TNF 
inhibitors, RA patients, AS patients and PsA patients have 
found more choices than ever before and have greater 
hope of sustained relief. As a widely used TNF inhibitor, 
infl  iximab has a deep and established record of effi   cacy 
and safety data. Extensive evidence – from randomised 
controlled clinical trials, large registries and post-
marketing surveillance studies – shows that infl  iximab 
eff  ectively treats the signs and symptoms, provides rapid 
and prolonged suppression of infl  ammation, prevents 
radiologically observable disease progression and off  ers 
an acceptable safety profi  le in RA, AS and PsA. In very 
recent studies, investigators have observed drug-free 
remission in some patients. Additionally, infl  iximab 
may interfere with rapidly progressing disease in RA by 
early addition to methotrexate in patients with signs 
of an aggressive course. Finally, infl  iximab has been 
shown to reduce PsA clinical manifestations such as 
nail involvement. With our current understanding, 
substantial data and increasing confi  dence regarding 
use in practice, infl  iximab can be considered a well-
known drug in our continued campaign against 
infl  ammatory rheumatic diseases.
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© 2011 BioMed Central Ltdinter  fere with the associated radiographic changes [19] 
and are the cornerstone of symptom control, even though 
not all patients beneﬁ  t [20]. In mild PsA, nonsteroidal 
anti-inﬂ  ammatory drugs may also be suﬃ   cient to control 
symptoms and joint damage, since the disease’s 
propensity to destroy joints is frequently not high. In RA, 
however, nonbiologic (synthetic) disease-modifying anti-
rheumatic drugs (DMARDs) (for example, sulphasalazine, 
methotrexate (MTX), leﬂ  unomide) are the mainstay of 
treatment, since they interfere not only with the signs 
and symptoms but also with progression of joint damage 
in many patients. Th  ese drugs also are eﬀ  ective in PsA; 
they have limited or no eﬃ   cacy in axial AS, however, 
despite being eﬀ  ective in the other chronic inﬂ  ammatory 
joint diseases and in peripheral arthritis of patients with 
AS [21,22].
Corticosteroids also have DMARD properties [23]. In 
RA, they are used in combination with synthetic DMARDs 
such as MTX (bridging therapy) to induce more rapid 
reduction of disease activity, and then are rapidly tapered. 
Corticosteroids are also used to treat oligoarthritis in 
PsA, although reactivation of psoriasis may occur upon 
steroid tapering. In AS, local corticosteroids can relieve 
site-speciﬁ  c inﬂ  ammation, but systemic use in axial AS is 
not supported by available evidence [22]. Long-term use 
of these drugs is limited by their side-eﬀ  ect  proﬁ  le 
[24,25].
Although synthetic DMARDs are eﬀ   ective in many 
patients with RA and PsA, a considerable number require 
a diﬀ   erent approach. Until the advent of biologic 
therapies, alternative medications did not exist and 
treatments often did not suﬃ   ciently control symptoms, 
joint damage and impairment of physical function. 
Consequently, conﬁ   ne  ment to a wheelchair and rapid 
loss of work ability were not infrequent. As understanding 
of the central inﬂ   am  matory mechanism has improved 
and the role of TNF has been elucidated, however, 
therapies have shifted from mere interference with the 
magnitude of the inﬂ  am  ma  tory response to its abrogation 
and thus toward halting progression of joint damage and 
restoring physical function and work ability. Interference 
with the pro  inﬂ  ammatory cytokine cascade using TNF 
inhibitors, but also interfering with other biological 
targets, may rapidly suppress and control inﬂ  ammation 
and thereby prevent irreversible tissue damage and 
disability [26].
For a long time, only three TNF inhibitors were avail-
able for the treatment of RA, AS and PsA: adalimumab, 
etanercept and inﬂ   iximab. Etanercept and inﬂ  iximab 
were approved for the treatment of RA within a year of 
each other (1998 and 1999, respectively) in the United 
States and in the same year (2000) in Europe. Worldwide 
patient exposures for these three agents total almost 
2  million patients [27-29].
Inﬂ   iximab was the ﬁ   rst biologic agent shown to be 
eﬃ   cacious in RA, AS and PsA [30]. Later studies revealed 
that combination inﬂ   iximab plus MTX tended to be 
superior to monotherapy [31], dramatically aﬀ  ected joint 
damage [32] and inhibited joint damage even in the 
absence of a clinical response, thus fostering the dissocia-
tion hypothesis (see Early rheumatoid arthritis, below) 
[33]. Th   at these inﬂ  iximab data were paradigmatic for the 
new class of TNF inhibitors has been shown in studies of 
other agents that fully conﬁ  rmed the inﬂ  iximab results 
[34-37]. An examination of the wealth of clinical data 
amassed over 12 years of experience with inﬂ  iximab from 
its ﬁ  rst licensing in Crohn’s disease (1998 in the United 
States) can thus tell us much about the state – and future – 
of TNF inhibitor therapy in RA, AS and PsA.
Whilst etanercept is not suﬃ   ciently  eﬃ   cacious  in 
Crohn’s disease, the three TNF inhibitors appear to have 
similar eﬃ   cacy in RA, PsA and AS. In the present review, 
we focus on inﬂ   iximab as a prototypical example for 
these eﬀ  ects.
Long-term infl  iximab use
Th  e available data reveal that inﬂ  iximab provides rapid 
and prolonged suppression of inﬂ  ammation and inhibits 
progression of joint damage in many patients with RA 
and PsA [38-41]. In addition, TNF inhibition – such as 
that with inﬂ   iximab – induces almost complete and 
sustained resolution of spinal inﬂ   ammation in many 
patients with AS [42,43].
Effi   cacy in rheumatoid arthritis
Inﬂ  iximab has emerged as a highly eﬀ  ective treatment in 
both early and established RA [32,40,44,45].
Early rheumatoid arthritis
Eﬃ   cacy in patients with early RA is critically important, 
since it is now understood that progression in inﬂ  am-
mation severity and joint damage is slow in some patients 
and more rapid in others [46,47]. Rapidly progressing 
patients should be identiﬁ  ed early in their disease course 
because they may beneﬁ  t from more intensive therapy. 
Th  e best predictors of rapidly progressing RA are 
currently the number of swollen joints, the presence of 
autoantibodies (high-titre rheumatoid factor and anti-
citrullinated peptide antibodies) and elevated acute-phase 
response (as measured by the erythrocyte sedimentation 
rate (ESR) or C-reactive protein (CRP) level) [47-50].
In the ASPIRE trial, the eﬃ   cacy of inﬂ  iximab (3 or 
6 mg/kg infusions at weeks 0, 2 and 6 and every 8 weeks 
thereafter) plus MTX (titrated up to 20 mg/week by week 
4) was assessed in 1,004 MTX-naïve patients with early 
(≥3 months, ≤3 years), moderate-to-severe active RA 
over a 54-week period [45]. Inﬂ  iximab plus MTX pro-
vided signiﬁ   cantly greater clinical, radiological and 
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RA. At week 54 there were no signiﬁ  cant diﬀ  erences in 
clinical eﬃ     cacy between the inﬂ   iximab groups – but 
compared with MTX alone, the American College of 
Rheumatology (ACR)-N, ACR20, ACR50 and ACR70 
response rates were signiﬁ  cantly higher with inﬂ  iximab. 
From baseline to week 54, the change in radiological 
progression was signiﬁ   cantly less in patients receiving 
inﬂ  iximab 3 mg/kg plus MTX and inﬂ  iximab 6 mg/kg 
plus MTX than in those receiving MTX alone (van der 
Heijde–Sharp scores, 0.4 ± 5.8, 0.5 ± 5.6 and 3.7 ± 9.6, 
respectively; Figure 1). In addition, improvements in 
physical function (Health Assessment Questionnaire) 
were signiﬁ  cantly greater in both inﬂ  iximab treatment 
groups compared with the MTX-alone group [45].
Another report from the ASPIRE trial investigated the 
prognostic value of disease activity markers (laboratory, 
clinical and radiographic) in relation to progression of 
joint damage [50]. In patients receiving MTX alone, a 
higher swollen joint count, higher ESR and CRP levels 
and higher rheumatoid factor levels at baseline were 
signiﬁ  cantly correlated with greater joint damage at week 
54. Th  is corre  lation was abrogated in patients treated 
with inﬂ  iximab plus MTX because of the marked eﬀ  ects 
on joint damage irrespective of the underlying disease 
activity or auto  antibody state. An additional analysis that 
adjusted for baseline demographic and other clinical 
charac  ter  istics still found an increased ESR and increased 
swollen joint counts to be signiﬁ  cantly associated with 
greater joint damage at week 54 in the MTX-alone group. 
Neither of these markers, however, was predictive of 
greater joint damage in the inﬂ  iximab-plus-MTX group. 
Th  e Disease Activity Score in 28 joints (DAS28) was 
mostly high at baseline in all patients; decreases were 
seen after 12 weeks. At 14 weeks, patients in the MTX-
alone group who had higher DAS28 scores showed 
greater progression of joint damage at week 54 than those 
in the group with lower scores. Again, no such correlation 
was noted in the inﬂ  iximab-plus-MTX group.
Radiographic progression, as determined by van der 
Heijde–Sharp scores, was also greatest in the portion of 
the MTX-only group that had the highest baseline CRP 
level and ESR: at 54 weeks, the score changed by 1.81 
points (± 7.27) in patients with normal CRP levels and 
ESR, and by 4.71 points (± 10.69) in patients with high 
CRP levels (≥0.8 mg/dl) and high ESR (>15 to 20 mm/
hour) [50]. In the inﬂ  iximab-plus-MTX group, however, 
the baseline CRP level and ESR had little association with 
radiographic progression; inﬂ  iximab plus MTX inhibited 
radiographic progression regardless of baseline disease 
activity or joint damage. In fact, all anti-TNF agents, 
when combined with MTX, are very eﬀ  ective in prevent-
ing radiological damage.
Importantly, only patients attaining stringent remission 
by the criteria of the simpliﬁ  ed disease activity index at 
week 14 did not progress radiologically irrespective of 
therapy; while those on MTX, when attaining low or 
higher categories of disease activity at week 14, pro-
gressed with increasing disease activity state. In contrast, 
inﬂ  iximab plus MTX halted radiologic progression even 
if patients had achieved low or moderate disease activity 
at week 14 [51], conﬁ  rming previous notions that this 
treatment dissociates the traditional link between inﬂ  am-
mation and destruction [33]. According to this dissocia-
tion hypothesis, treatment reduces the impact of inﬂ  am-
mation on destruction to the extent that some pro-
gression of damage is seen only in patients with very high 
levels of un  suppressed inﬂ  ammation (Figure 2). Whether 
stringent remission was achieved at 3 months or 1 year, 
there was an almost linear increase in progression of joint 
damage with MTX, reaching approximately 6 radio-
graphic score points with high disease activity (Figure 2). 
Th   e radiographic progres  sion was not only fully or mostly 
abrogated with inﬂ  iximab plus MTX in remission, but 
also in low and even moderate disease activity [51]. 
Nevertheless, even with combination therapy there was a 
link between disease activity and progression of joint 
damage, although the slope was dramatically diverted. 
Th  erefore, although there is still a connection between 
inﬂ  ammation and destruction, TNF-inhibitor-plus-MTX 
treatment reduces the impact of inﬂ  ammation  on 
destruction to the extent that progressive damage is seen 
only in cases with high levels of unsuppressed 
inﬂ  ammation – but even then to a lesser degree than 
upon treatment with MTX alone.
Figure 1. Early rheumatoid arthritis: radiological progression. 
Infl  iximab plus methotrexate (MTX) reduces progression of joint 
damage in rheumatoid arthritis compared with MTX alone (P < 0.001 
at weeks 30 and 54) [45]. vdH-S, van der Heijde–Sharp.
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Although the eﬃ   cacy of MTX is appreciable, patients 
with rapidly progressing disease (RPD) may obtain 
additional beneﬁ  t from more intensive therapy. Th  e  CRP 
level and ESR may serve as predictors of future joint 
damage in patients with early RA who are treated with 
MTX monotherapy and may allow potentially optimal 
management with the earlier addition of a TNF inhibitor. 
Although few studies have been performed in patients 
with RPD despite MTX therapy, analyses of subsets of 
these patients have demonstrated improved long-term 
beneﬁ  ts with the early addition of inﬂ  iximab [33,52,53]. 
Inﬂ  iximab has been evaluated in this regard in both early 
and long-term disease with similar results. Likewise, 
starting these patients on etanercept monotherapy or 
adalimumab plus MTX has shown similar eﬃ   cacy 
[54,55]. Th   e GUEPARD trial, however, showed that rapid 
addition of a TNF inhibitor to a DMARD – if the latter 
has not been suﬃ   ciently eﬀ  ective within 3 to 6 months – 
provides clear-cut beneﬁ  t similar to that derived from 
starting with combination anti-TNF and DMARD 
therapy [56].
Th   e prediction of RPD in patients with RA represents 
an intriguing challenge for tailoring biologic therapy and 
an exciting development in the ﬁ   eld. Two pilot risk 
models for predicting RPD in RA patients were recently 
proposed [47]. ASPIRE data were used to deﬁ  ne RPD and 
to identify baseline risk factors; in line with previous data 
[50], these risk factors were swollen joint counts, 
rheumatoid factor levels, CRP levels and the ESR. Th  e 
results were then combined with initiated treatments and 
arranged in matrices that allow prediction of risk in 
1 year (Figure 3). One model incorporated all risk factors 
except the CRP level, and the other model incorporated 
all risk factors except the ESR, to enable interchangeable 
use depending on clinical availability. Both models 
identiﬁ  ed subpopulations of RA patients at higher pre-
dicted risk of RPD, particularly those who were MTX-
naïve with early disease. Additional develop  ment plus 
testing of the models in other RA populations is needed 
(and currently in progress) to produce a single tool that 
would be practical and validated for use in everyday 
practice.
Very early transient treatment with inﬂ  iximab has been 
shown to be eﬀ  ective in early, poor-prognosis RA. In a 
randomised, double-blind study, 20 previously untreated 
patients with early (<12 months), poor-prognosis RA 
(deﬁ   ned by the Persistent Inﬂ  ammatory  Symmetrical 
Arthritis scoring system) were randomised to receive 
inﬂ  iximab plus MTX (3 mg/kg) or placebo plus MTX for 
12 months [53]. After 1 year of treatment, magnetic 
resonance imaging (MRI) evidence of synovitis and joint 
damage was reduced (with signiﬁ   cantly fewer new 
erosions) in inﬂ  iximab-treated patients compared with 
Figure 2. Early rheumatoid arthritis: disease activity. Changes in total Sharp score (TSS) by disease activity states, as classifi  ed by the simplifi  ed 
disease activity index. IFX, infl  iximab; MTX, methotrexate; NS, not signifi  cant. Modifi  ed from [51].
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ing inﬂ  iximab plus MTX than those receiving MTX alone 
were ACR50 responders (78% and 40%, respectively) and 
ACR70 responders (67% and 30%, respectively). Further-
more, greater improvements in physical function (Health 
Assessment Questionnaire) and quality of life (QoL) 
(determined by the Rheumatoid Arthritis Quality of Life 
questionnaire) were seen throughout the 12 months of 
treatment in the inﬂ  iximab-plus-MTX group. Treatment 
was stopped after 1 year, and the patients were then 
followed for another 12 months. One year post 
inﬂ   iximab-plus-MTX therapy, clinical response was 
sustained in 70% of the patients in this group, with a 
median DAS28 of 2.05. Signiﬁ   cant improvements in 
function and QoL were also sustained [53].
Th   e BeST study, a randomised trial that assessed four 
diﬀ  erent treatment strategies in 508 patients with recent-
onset RA, showed similar results. Over year 1, patients 
receiving initial combination therapy with tapered high-
dose prednisone plus MTX plus sulphasalazine (group 3, 
133 patients) or inﬂ   iximab plus MTX (group 4, 128 
patients) had more rapid functional improvement and 
less progression of radiographic joint damage than 
patients treated with sequential monotherapy (group 1, 
126 patients) or step-up combination therapy (group 2, 
121 patients), and the diﬀ  erences at most time points 
were signiﬁ  cant [57]. Th   e BeST study also demonstrated 
that clinical and functional beneﬁ   ts of inﬂ  iximab plus 
MTX were maintained over 4 years [58,59]. In addition, 
the study provided important information about remis-
sion in RA. After 2 years of inﬂ  iximab  combination 
therapy, 67 out of 120 patients in group 4 (56%) were able 
to discontinue treatment, and 40 out of the 67 (33% of the 
total group 4 population) achieved clinical remission 
[60]. Moreover, signiﬁ  cantly more patients in this group 
(16%) maintained clinical remission oﬀ   inﬂ  iximab than in 
groups 2 and 3, who received inﬂ   iximab later in the 
course of their treatment (6% and 7%, respectively; 
P <0.05 for all) [58]. (Th  e diﬀ  erence between groups 1 
and 4 was not signiﬁ  cant.) After 3 years of combination 
therapy, 31% of patients in group 3 and 48% of patients in 
group 4 were able to taper their medication to DMARD 
monotherapy or no DMARD. Finally, at year 4 – when 61 
out of 120 patients (51%) were oﬀ   inﬂ  iximab – 20 out of 
Figure 3. Rapidly progressing disease in rheumatoid arthritis. Matrix risk model for the probability of rapid radiographic progression (RRP) in 1 
year, including all selected baseline risk factors, except (a) erythrocyte sedimentation rate (ESR) or (b) C-reactive protein (CRP), generated from the 
ASPIRE early rheumatoid arthritis dataset. Numbers in each cell represent the percentage (95% confi  dence interval) of patients who had RRP out of 
all patients who have the baseline characteristics and receive the initiated treatment as indicated. Predicted probability of RRP: blue, 0 to 9%; green, 
10 to 19%; yellow, 20 to 29%; orange, 30 to 39%; red, 40 to 100%. A higher percentage indicates more severe radiographic progression of joint 
damage. IFX, infl  iximab; mono, monotherapy; MTX, methotrexate; RF, rheumatoid factor; SJC, swollen joint count. Reprinted with permission from 
[47].
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average 1 year [59].
Six-year BeST data were presented at the October 2009 
ACR scientiﬁ  c meeting. Of the original 508-patient study 
population, 99 patients (19%) withdrew over 6 years. Of 
the remaining 409 patients, 51% were in clinical 
remission at 6 years, and 17% (36 patients) of those in 
remission were in prolonged drug-free remission [61].
Established rheumatoid arthritis
Inﬂ  iximab has also demonstrated eﬃ   cacy in patients with 
established RA. Th  e ATTRACT study evaluated the 
eﬃ   cacy of inﬂ  iximab in 428 patients with active RA of 
7.2-year to 9-year duration, despite 3 months or more of 
MTX therapy [32,40,44]. Patients received 3 mg/kg or 
10 mg/kg infusions of inﬂ  iximab at weeks 0, 2 and 6 and 
then at 4 or 8 weeks thereafter in combination with 
MTX. Th   is randomised, double-blind, placebo-controlled 
phase III study showed that inﬂ   iximab plus MTX is 
eﬀ  ective in controlling the signs and symptoms of estab-
lished RA. After 30 weeks of assessment, 51.8% of 
patients receiving any dose of inﬂ   iximab plus MTX 
demon  strated a clinical response (≥20% improvement 
from baseline using ACR assessment criteria (ACR20)) 
compared with only 17% of patients receiving placebo 
plus MTX [32,44]. Furthermore, approximately 30% of 
inﬂ  iximab-plus-MTX patients achieved a 50% improve-
ment from baseline compared with only 5% of placebo-
plus-MTX patients [44].
Th   e ATTRACT study also showed that inﬂ  iximab plus 
MTX signiﬁ  cantly reduced progression of structural joint 
damage in RA compared with MTX alone [32]. After 
1 year of treatment, inﬂ  iximab plus MTX prevented the 
progressive joint damage associated with inﬂ  ammation 
and resulted in a signiﬁ  cant reduction in progression of 
radiological changes, using the modiﬁ  ed van der Heijde–
Sharp score, in a signiﬁ  cant proportion of patients com-
pared with placebo plus MTX (van der Heijde–Sharp 
scores, 1.63 and 6.95, respectively; Figure 4). Interestingly, 
the ATTRACT study also assessed the relationship 
between inﬂ  ammation and joint destruction in patients 
not suﬃ   ciently responding clinically to inﬂ  iximab plus 
MTX (ACR20 nonresponders), and found that inﬂ  iximab 
plus MTX still provided inhibition of structural damage 
compared with placebo (plus insuﬃ   ciently  eﬀ  ective 
MTX) [32]. Th   ese results suggest that these two disease 
measures, which are usually tightly linked, are dissociated 
under this treatment (Figure 5) [33]. Th   is suggestion was 
conﬁ   rmed when it was shown that joint damage was 
retarded even in patients who had no improvement in 
disease activity measures [33], and similar ﬁ  ndings were 
made in early RA [51], as discussed above (see Figure 2).
Studies of long-term inﬂ  iximab therapy have demon-
strated that the positive eﬀ   ects on joint damage are 
sustained. For example, at the end of ATTRACT year 2, 
the data showed signiﬁ  cant improvements in clinical res-
ponse and inhibition of progressive joint damage with 
inﬂ   iximab plus MTX compared with placebo (plus 
Figure 4. Established rheumatoid arthritis: progression of structural joint damage. Infl  iximab (IFX) plus methotrexate (MTX) signifi  cantly 
reduces progression of structural joint damage compared with MTX alone, after 1 year of treatment. All patients received concomitant MTX [32]. 
P < 0.001 for all doses and courses. vdH-S, van der Heijde–Sharp.
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receiv ing  inﬂ   iximab plus MTX not only continued to 
have good clinical responses and inhibition of progressive 
joint damage during that 2-year period, but also experi-
enced signiﬁ  cant improvements in physi  cal function (as 
determined by the self-administered Health Assessment 
Questionnaire) and health-related QoL (as determined by 
the Short-form 36 Health Survey) com  pared with patients 
receiving placebo (plus insuﬃ   ciently eﬀ  ective MTX) [40].
Another study of 511 patients with longstanding, 
refractory RA found that long-term maintenance therapy 
with inﬂ  iximab continues to reduce disease activity [62]. 
Th  e researchers also examined 4-year compliance rates 
and found that a majority of patients continued treat-
ment. Inﬂ  iximab was well tolerated, and 61.6% of patients 
were still receiving this treatment at the 4-year point [62]. 
Th   e main reasons for discontinuing therapy were lack of 
eﬃ   cacy (13.6%) and safety issues (16.9%). Th   is study is in 
line with smaller studies demonstrating 3-year inﬂ  iximab 
continuation rates of 58 to 75% [63-68].
Effi   cacy in ankylosing spondylitis
Inﬂ  iximab induces a rapid reduction in disease activity in 
patients with AS. Th  e TNF-inhibitor aﬀ  ects the under-
lying inﬂ  ammation of both articular and extra-articular 
mani  fes  tations of AS [2,12,69,70]. Signiﬁ  cant  eﬃ   cacy 
compared with placebo was ﬁ  rst reported by Braun and 
colleagues in a random  ised, double-blind study of 69 
patients with active AS [71]. After 12 weeks of treatment, 
53% of patients receiving inﬂ  iximab (5 mg/kg) had ≥50% 
reduction in disease activity, as measured by the Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI), 
compared with 9% of patients receiving placebo 
(Figure  6). Th  e physical function, as measured by the 
Bath Ankylosing Spondylitis Functional Index, and QoL 
(Short-form 36 Health Survey) also signiﬁ  cantly  im-
proved in inﬂ   iximab-treated patients compared with 
placebo-treated patients (both P <0.0001).
After the 12-week, placebo-controlled phase of this 
study, all patients entered a 3-year open-label extension. 
Sixty-two per cent (43 out of 69 patients) completed 
3 years of inﬂ  iximab treatment and then discontinued to 
allow assessment of the time to ﬂ   are. Most patients 
relapsed within 18 to 24 weeks, and 42 out of 43 patients 
restarted inﬂ  iximab, with most regaining eﬃ   cacy. Good 
clinical response was sustained for 5 years, with 63%, 
58%, 61% and 63% of patients achieving at least a 50% 
reduction in disease activity (BASDAI) from baseline 
after 1, 2, 3 and 5 years of treatment, respectively 
(Figure  7) [72-74]. Th  e Assessment of the Spondylo-
Arthritis International Society (ASAS) ASAS40 response 
was seen in 75% and 63% of patients at the end of years 3 
and 5, respectively. Similarly, an ASAS5/6 response was 
achieved in 76% and 71% of patients at the end of years 3 
Figure 5. Established rheumatoid arthritis: infl  ammation and joint destruction. Mean change from baseline to week 54 in modifi  ed van der 
Heijde–Sharp score among patients who remained clinical nonresponders from week 2 through week 54, by treatment group. Corresponding 
median changes in the methotrexate (MTX)-plus-placebo-treated group (placebo) and the groups receiving infl  iximab (IFX) 3 mg/kg every 8 weeks 
plus MTX, IFX 3 mg/kg every 4 weeks plus MTX, IFX 10 mg/kg every 8 weeks plus MTX, and IFX 10 mg/kg every 4 weeks plus MTX, as well as all 
IFX-plus-MTX groups were 3.50, 0.27, –0.50, –0.25, 1.25 and 0.00, respectively. *P <0.05, **P <0.01 versus MTX-plus-placebo-treated patients. Dosage 
and frequency data (4 weeks, 8 weeks) refer to infl  iximab treatment. Modifi  ed with permission from [33].
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(BASDAI value <3 units) was attained in 57.9% of 
patients after 5 years; the mean BASDAI was 2.5 ± 1.9 
(baseline, 6.4; at 3 years, 2.5) [74]. Partial clinical remis-
sion (score ≤2 in each of the four ASAS domains) was 
reached by 37% and 34% of patients at the end of years 3 
and 5, respectively [74]. Th  e time to ﬂ  are  during 
discontinuation suggested that continuous therapy is 
necessary to achieve a lasting eﬀ   ect in patients with 
severe, active AS.
Th  e ASSERT trial also provided evidence for the 
eﬃ   cacy and safety of inﬂ  iximab (5 mg/kg) in patients 
with AS [75]. In this randomised, placebo-controlled 
study of 279 patients, the clinical response was rapid, as 
early as 2 weeks, and was sustained over 24 weeks, with 
61.2% of inﬂ  iximab patients achieving ASAS20 compared 
with 19.2% of placebo patients at week 24 (P <0.001). In 
addition, 47% of patients in the inﬂ  iximab group were 
ASAS40 responders compared with 12% of patients in 
the placebo group at week 24 (Figure 8). Signiﬁ  cant 
improvements in the BASDAI and the Bath Ankylosing 
Spondylitis Functional Index were also seen in the 
patients receiving inﬂ  iximab.
Inﬂ  iximab induced a pronounced reduction in spinal 
inﬂ   ammation in MRI examinations of patients in the 
ASSERT study. Th   e MRI activity score improved signiﬁ  -
cantly more in inﬂ  iximab-treated patients (mean, 5.02; 
median, 2.72) compared with placebo patients (mean, 
0.60; median, 0.0) from baseline to week 24 [42]. Most 
inﬂ  iximab-treated patients achieved complete resolution 
of spinal inﬂ  ammation (Figure 9).
Th  e reduction in spinal inﬂ  ammation with inﬂ  iximab 
was sustained over the long term. At week 24 of the 
ASSERT study, placebo patients crossed over to receive 
inﬂ  iximab (5 mg/kg) as part of an open-label extension 
[43]. Short-tau inversion recovery MRI images were 
taken at baseline and at weeks 24 and 102. Patients in the 
inﬂ  iximab group showed improvement in the Ankylosing 
Spondylitis MRI Spinal Score for Activity at week 24 
(mean, –4.4; median, –2.00) compared with no change in 
the placebo group (mean, 0.38; median, 0.25), and this 
improvement was sustained through 102 weeks [43]. 
Patients in the placebo group improved after crossing 
over to receive inﬂ  iximab at week 24, and subsequently 
achieved similar levels of spinal inﬂ  ammation reduction 
by week 102 as patients receiving inﬂ  iximab from the 
start. Interestingly, however, and contrasting with results 
in RA, inﬂ  iximab does not appear to halt progression of 
radiographic changes; likewise, structural changes also 
progressed on etanercept treatment, contrasting the 
clinical eﬀ  ects [75,76].
In another study, 40 patients in whom early sacroiliitis 
had been determined by MRI were randomised in a 
double-blind manner to inﬂ  iximab 5 mg/kg or placebo at 
0, 2, 6 and 12 weeks. Both MRI and clinical assessment at 
16 weeks showed signiﬁ  cantly reduced disease activity. 
For example, signiﬁ  cantly more lesions resolved in the 
inﬂ  iximab group (P <0.001), while signiﬁ  cantly more new 
lesions developed in the placebo group (P = 0.004) [77].
Inﬂ  iximab was also found to mitigate extra-articular 
manifestations of AS, which can reduce QoL and signal 
worse outcomes. For example, patients with AS have a 20 
to 30% risk of uveitis [78], and a meta-analysis showed 
that inﬂ  iximab  signiﬁ   cantly reduced the incidence of 
uveitis compared with placebo (P  = 0.005) [70]. Sub-
clinical inﬂ  ammation of the gut is present in up to 60% of 
Figure 6. Ankylosing spondylitis: disease activity. Infl  iximab rapidly reduces disease activity compared with placebo (n = 70 patients). 
Percentage of patients with improvement ≥50% in the Bath Ankylosing Spondylitis Disease Activity Index. P <0.0001 from 2 weeks onwards. 
Modifi  ed with permission from [71].
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blown inﬂ  ammatory bowel disease [79]. Another meta-
analysis showed that inﬂ  iximab  signiﬁ  cantly  reduced 
incidence rates of ﬂ   ares or new-onset inﬂ  ammatory 
bowel disease compared with etanercept (P = 0.001) and 
adalimumab (P = 0.02) [80]. Similarly, a subanalysis of the 
ASSERT trial’s 24-week phase demonstrated signiﬁ  cant 
increases in mean spinal bone density in AS patients 
treated with inﬂ  iximab compared with placebo (P <0.001) 
[81]. Th  e eﬀ  ects on vertebral fracture, however, are not 
yet known.
Effi   cacy in psoriatic arthritis
Inﬂ  iximab is eﬀ  ective in treating various aspects of PsA, 
including joint symptoms and extra-articular manifesta-
tions such as dactylitis, enthesitis and nail disease, as well 
Figure 7. Ankylosing spondylitis: improvement in disease activity. Infl  iximab sustains improvement in disease activity over 5 years. At 
156 weeks, n = 43 patients; at 254 weeks, n = 38. ASAS, Assessment of SpondyloArthritis International Society; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; IFX, infl  iximab. Modifi  ed with permission from [74].
Figure 8. Ankylosing spondylitis: rapid clinical response. Infl  iximab rapidly improves ASAS40 compared with placebo (n = 279 patients). 
P <0.001 from 2 weeks onwards. ASAS, Assessment of SpondyloArthritis International Society. Modifi  ed with permission from [75].
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in PsA was assessed in the IMPACT 1 and IMPACT 2 
studies [82,83]. Th   ese studies were similar in design, with 
a 16-week to 24-week, randomised, placebo-controlled 
phase, after which all patients received inﬂ  iximab for up 
to 1 year. Both studies measured articular and composite 
disease assessment, skin symptoms, enthesitis, dactylitis 
and QoL. Enrolled patients had active PsA that was 
unresponsive to at least one DMARD.
Signiﬁ  cant improvements were observed in the signs 
and symptoms of articular disease. In the IMPACT 1 
study (n = 104), 65.4% of patients treated with inﬂ  iximab 
were ACR20 responders at week 16 compared with only 
9.6% of placebo patients (Figure 10a) [82]. Furthermore, 
46.2% and 28.8% of inﬂ   iximab-treated patients were 
ACR50 and ACR70 responders, respectively, compared 
with none of the placebo patients at week 16. Similar 
improvements were seen in the IMPACT 2 study (n = 200): 
58% of inﬂ  iximab-treated patients and 11% of placebo 
patients achieved an ACR20 response at week 14 
(P <0.001) [83]. Forty-one per cent and 27% of patients in 
the inﬂ  iximab group were ACR50 and ACR70 respon-
ders, respectively, compared with 4% and 2% of placebo 
patients, respectively, at week 24. Th  e improvement in 
joint symptoms was sustained throughout both studies 
(up to 54 weeks) [82,84]. In IMPACT 1, for example, the 
proportion of ACR20 responders in the group of placebo 
patients who crossed over to inﬂ  iximab treatment was 
similar to the proportion of ACR20 responders in the 
group of patients who received inﬂ  iximab from day 1: 
68% and 69%, respectively (Figure 10b) [82].
Inﬂ  iximab also inhibits the radiological progression of 
joint damage in PsA [41,85]. During the placebo-
controlled phase (weeks 1 to 24) of the IMPACT 2 study, 
radiographs of the hands and feet showed signiﬁ  cantly 
less progression of structural damage in inﬂ  iximab 
patients compared with placebo patients (mean change 
from baseline in modiﬁ  ed van der Heijde–Sharp score, 
–0.70 and 0.82, respectively) [41]. Th  e mean annual 
progression rate at baseline was equivalent to 5.8 modi-
ﬁ   ed van der Heijde–Sharp points/year for the overall 
study population, but the projected rate for the overall 
population post inﬂ  iximab was –1.79 [85]. In fact, 84.3% 
of the total patient population did not have radiographic 
progression after a year of inﬂ  iximab treatment [85].
Inﬂ   iximab also improved physical function in PsA 
regard  less of baseline radiographic damage. After 
54 weeks of treatment, the percentage improvement in 
the Health Assessment Questionnaire was strikingly 
better than at baseline in both treatment groups [84]. 
Importantly, those patients with less radiological damage 
regained function more quickly, suggesting that thera-
peutic intervention early in the disease course may limit 
the amount of joint damage.
Additionally, inﬂ   iximab was eﬀ   ective in treating 
psoriatic skin symptoms. In the IMPACT 1 study, 
inﬂ   iximab-treated patients with a Psoriasis Area and 
Severity Index (PASI) score ≥2.5 at baseline had a mean 
improvement from baseline in PASI score of 86% 
compared with a 12% deterioration in placebo patients 
(P  <0.001) [82]. Of these, 68% of inﬂ  iximab-treated 
patients achieved an improvement in PASI score ≥75% 
compared with none of the placebo patients (P <0.001). 
Improvements were maintained over 50 weeks (Figure  11). 
Similar ﬁ  ndings were observed in the IMPACT 2 study; 
64% of patients with skin involvement treated with 
inﬂ  iximab achieved an improvement in PASI ≥75% com-
pared with 2% of placebo patients (P <0.001) [83]. Inter-
est  ingly, another study observed a correlation between 
skin response and improvement in joint symptoms in 
PsA patients treated with inﬂ  iximab. Patients with a good 
skin response had a greater joint response than those 
with no skin response [86].
Th  e IMPACT 2 study also evaluated the eﬀ  ect  of 
inﬂ  iximab on the incidence of other typical features of 
PsA. Dactylitis was less frequent in inﬂ  iximab-treated 
patients than placebo patients at both week 14 (18% vs. 
30%,  P  = 0.025) and week 24 (12% vs. 34%, P  <0.001). 
Enthesopathy was also less frequent in inﬂ  iximab-treated 
patients than in placebo patients at both week 14 (22% vs. 
34%, P = 0.016) and week 24 (20% vs. 37%, P = 0.002) [83].
Th   e EXPRESS trial was the ﬁ  rst large, controlled, phase 
III clinical study to use the Nail Psoriasis Severity Index 
tool in patients with psoriasis [87]. Of the 378 patients 
randomised, 114 (30.2%) had a history of PsA. Among 
the 373 patients evaluated for nail disease, it was found to 
be present at baseline in 87.5% of patients (98 out of 112) 
with a history of PsA and in 79.3% of patients without a 
Figure 9. Ankylosing spondylitis: spinal infl  ammation. Infl  iximab 
completely resolves spinal infl  ammation in most patients: (a) before-
treatment and (b) after-treatment gadolinium-enhanced T1 images. 
STIR, short-tau inversion recovery. Reproduced with permission from 
[42].
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improve  ments in nail bed scores in patients receiving 
inﬂ  iximab versus those receiving placebo were 69.2% and 
18.4%, respectively; the percentage improve  ments in nail 
matrix scores were 52.9% and –1.9%, respec  tively 
(P <0.001). Signiﬁ  cant and comparable degrees of improve-
ment were observed, regardless of baseline history of 
PsA. Th   e Nail Psoriasis Severity Index values persevered 
in both groups at weeks 38 and 50 (placebo crossover to 
inﬂ  iximab occurred at week 24), also regardless of PsA 
history.
Th   e recently concluded RESPOND trial investigated an 
aggressive strategy in early, severe polyarticular PsA [88]. 
Th   is study compared the eﬃ   cacy and safety of inﬂ  iximab 
5 mg/kg plus MTX with MTX alone in MTX-naïve 
subjects who had an inadequate response to steroids and 
nonsteroidal anti-inﬂ  ammatory drug therapy. Th  e  primary 
end point (ACR20 at week 16) was achieved in 44 out of 
51 patients (86.3%) in the inﬂ  iximab-plus-MTX group 
compared with 32 out of 48 patients (66.7%) in the MTX-
alone group (P = 0.021). Th   e ACR50 and ACR70 response 
rates at week 16 were also signiﬁ  cantly greater in the 
inﬂ  iximab-plus-MTX group, with 37 out of 51 patients 
(72.5%) achieving ACR50 (compared with 19 out of 48 
patients (39.6%) in the MTX-alone group; P  = 0.0009) 
and 25 out of 51 patients (49%) achieving ACR70 (com-
pared with nine out of 48 patients (18.8%) in the MTX-
alone group; P  = 0.0015). Overall, patients receiving 
inﬂ  iximab plus MTX showed more profound levels of 
disease suppression, as illustrated by DAS28 remission 
rates, an absence of swollen or tender joints, a normal 
CRP level and PASI 90 responses.
Safety considerations
With 12 years of clinical use and the availability of national 
disease registries, the safety proﬁ  le of TNF inhibitors is 
well characterised. Serious adverse events (SAEs) with 
inﬂ   iximab include: the development of viral, fungal or 
bacterial infectious diseases (for example, tuberculosis 
(TB), listeriosis, sepsis, opportunistic infections due to 
Cryptococcus, Aspergillus and Pneumo  cystis); reactivation 
of hepatitis B virus; hepatobiliary disorders (for example, 
worsening of hepatitis C, chole  cystitis and cholelithiasis, 
very rare jaundice and non-infectious hepatitis); allergic/
infusion-related reactions (for example, anaphylaxis); 
malignancies (for example, lymphoma, nonmelanoma skin 
cancer); autoantibody formation (for example, lupus-like 
syndrome); haemato  logical reactions (for example, 
pancytopaenia, aplastic anaemia); neurological disorders 
(for example, optic neuritis, seizure, demyelinating 
disorders such as multiple sclerosis); and worsening of 
congestive heart failure [89]. In general, as with eﬃ   cacy, 
the safety aspects of TNF inhibitors are similar [90,91], 
and registries compile data on all of the biologics. Th  e  risks 
are thus recognised and are increasingly understood.
In an assessment of safety proﬁ  les for DMARDs and 
biologic agents in more than 10,000 patients with RA, no 
unexpected safety signals and no trends of concern were 
noted compared with data seen during earlier trials and 
in the early days of TNF-inhibiting therapies [92]. Th  e 
Figure 10. Psoriatic arthritis: improvement of joint symptoms. Infl  iximab signifi  cantly improves joint symptoms compared with placebo 
(P <0.001 at week 16) in the IMPACT 1 study (n = 104 patients) [82]. (a) Prior to crossover. (b) Open-label extension, up to 54 weeks. ACR, American 
College of Radiology.
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showed that rates of SAEs and and serious infections 
across multiple therapies were comparable with the rates 
observed with MTX treatment. Similar conclusions were 
drawn from an observational cohort of the Consortium 
of Rheumatology Researchers of North America registry, 
which included 18,305 RA patients [93]. Th  ere was no 
signiﬁ   cant increase in the adjusted risk for overall 
infections associated with anti-TNF therapy compared 
with MTX, and the infection-related safety proﬁ  les of the 
various biologic agents appeared to be similar.
Serious infection rates were calculated in a prospective, 
observational study of 7,664 patients treated with TNF 
inhibitors and 1,354 patients treated with DMARDs from 
the British Society for Rheumatology Biologics Register 
[94]. All patients had severe RA. Th  e crude rates of 
serious infections were found to be similar among TNF 
inhibitors: 51.3 events/1,000 person-years for etanercept, 
55.2 events/1,000 person-years for inﬂ  iximab and 51.9 
events/1,000 person-years for adalimumab. During the 
study period, however, there were 525 serious infections 
in the TNF-inhibitor cohort and 56 in the DMARD 
cohort (9,868 and 1,352 person-years of follow-up, 
respec tively).  Th   e incidence rate ratio, adjusted for base-
line risk, for the TNF-inhibitor cohort compared with the 
DMARD cohort was 1.03 (95% conﬁ  dence interval, 0.68 
to 1.57), suggesting similar risk levels between the two 
treatment groups. Th  e types of serious infections were 
diﬀ  erent between the groups, however, with 19 serious 
bacterial intracellular infections occurring exclusively in 
patients in the TNF-inhibitor cohort. After adjustment 
for baseline risk, anti-TNF therapy was not associated 
with an increased risk of overall serious infections com-
pared with DMARD treatment in patients with active RA 
[94]. Nevertheless, the data did show an increased risk of 
TB infection in patients treated with inﬂ  iximab and other 
anti-TNF therapies, although this risk might be lower 
with etanercept [95].
A large randomised, placebo-controlled trial assessed 
the risk of serious infections following inﬂ  iximab-plus-
MTX therapy in patients with active RA [96]. Th   e risk of 
serious infections in patients receiving inﬂ  iximab 3 mg/kg 
plus MTX was similar to that in patients receiving MTX 
monotherapy. Furthermore, most infections reported in 
clinical trials of TNF inhibitors were minor and were 
treated with either outpatient antibiotic therapy and/or 
temporary withdrawal of the drug [97].
A prospective cohort study of the German RA registry 
RABBIT compared the rates of infections in patients 
treated with the biologic agents inﬂ  iximab, etanercept 
and anakinra with the rates of infections in patients re-
ceiving conventional DMARDs. Among patients receiv-
ing inﬂ  iximab, 21% experienced a serious infection com-
pared with 6% of control patients. In addition, the 
incidence of adverse events in general was 3.3 to 4.1 
times higher in patients receiving biologic agents than in 
the control group [98].
Th  e immunosuppressive activity of TNF inhibitors 
conveys a theoretical risk of malignancy development. 
Postmarketing surveillance, however, reported lym-
phoma rates (mostly non-Hodgkin’s lymphoma) of 
between 0.01 and 0.03 events/100 patient-years in 
patients receiving TNF inhibitors [99]. Th   e expected rate 
was 0.07 events/100 patient-years in a normal population 
aged 65 years. Further  more, the potential rate of 
lymphoma was com  plicated by the association of some 
immune-mediated diseases, especially RA, with an 
inherent lymphoma risk [100]. Currently, no clear 
Figure 11. Psoriatic arthritis: improvement of skin symptoms. Infl  iximab improves skin symptoms in patients with psoriatic arthritis at week 16 
(P < 0.001) and after crossover in the IMPACT 1 study. PASI, Psoriasis Area and Severity Index. Modifi  ed from [82].
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established [101]. Cumulatively, 565 cases of lymphoma 
development have been reported among more than 1 
million patients since the launch of inﬂ  iximab.  Th  e 
cumulative rate for lymphoma per 100 patient-years since 
ﬁ   rst exposure is 0.017 [101]. Although a deﬁ  nitive 
conclusion regarding lymphoma risk with TNF inhibitors 
in general – and inﬂ  iximab in particular – cannot be 
reached at present, postmarketing pharmaco  vigilance 
continues to track lymphoma incidence.
Injection site or infusion reactions occur with all TNF 
inhibitors – but because inﬂ   iximab is a human-plus-
mouse (that is, chimeric) antibody, anaphylaxis is 
possible. Anaphylactic reactions are uncommon in 
patients receiving inﬂ  iximab [89]. In clinical trials, 5,706 
patients received 36,485 inﬂ  iximab infusions, for a mean 
of 6.4 infusions/patient, and 3,722 patients received 
15,379 placebo infusions, for a mean of 4.1 infusions/
patient. Overall, the frequency of infusion reactions was 
4% for inﬂ  iximab compared with 1.6% for placebo. Th  e 
majority of infusion reactions were mild to moderate (for 
example, nausea, headache, sweating, ﬂ  ushing). Th  e  rate 
of serious infusion reactions was 0.2% for inﬂ  iximab and 
zero for placebo [102,103]. Immunogenicity can also 
arise (incidence, 9 to 17%). Although the eﬀ  ect of im-
muno  genicity on eﬃ   cacy is unclear, patients who develop 
immunogenicity may be at higher risk for infusion 
reactions [100].
Long-term safety data for infl  iximab
Th  e beneﬁ  t:risk  proﬁ   le should be considered when 
selecting patients for inﬂ   iximab therapy. Th  e safety 
proﬁ  le for inﬂ  iximab is well established, and the labelling 
explains all risks (the following excerpts address TB, 
hepatitis and pregnancy):
Before starting treatment, all patients must be 
evalu  ated for active and inactive (‘latent’) tuber-
culosis [TB] according to local standards. In case 
of latent (or active) TB appropriate prophylactic 
(or therapeutic) measures have to be taken.
Reactivation of hepatitis B has occurred in 
patients receiving a TNF-inhibitor including 
inﬂ  ixi  mab, who are chronic carriers of this virus. 
Some cases have had fatal outcome. Risk for HBV 
[hepatitis B virus] infection has to be evaluated 
before initiating Remicade therapy. Carriers of 
HBV who require treatment with Remicade need 
to be closely monitored for signs and symptoms of 
active HBV infection throughout therapy and for 
several months following termination of therapy. 
Eﬀ  ective anti-viral therapy may be needed.
Post-marketing reports from approximately 300 
pregnancies exposed to inﬂ  iximab, did not indi-
cate unexpected eﬀ  ects on pregnancy out  come. 
Due to its inhibition of TNFα, inﬂ  iximab adminis-
tered during pregnancy could aﬀ  ect normal 
immune responses in the newborn. […] Since the 
available clinical experience is too limited to 
exclude a risk, inﬂ  iximab should not be adminis-
tered during pregnancy.
Remicade Summary of 
Product Characteristics, 2009 [89]
In RA, a meta-analysis of seven randomised controlled 
trials (n = 2,100 patients) of duration ≤1 year in patients 
receiving either inﬂ   iximab plus MTX or placebo plus 
MTX demonstrated that between-group diﬀ  erences for 
SAEs, serious infections, malignancy or death were not 
signiﬁ  cant. Th  e between-group diﬀ  erence for infections 
was close to signiﬁ  cance (P = 0.06) [104]. Th  e  inﬂ  iximab 
group had signiﬁ  cantly more infusion reactions than the 
placebo group (P = 0.02). Th   e number of withdrawals due 
to adverse events was also signiﬁ   cantly higher in the 
inﬂ   iximab group compared with the control group 
(P  =  0.001). A network meta-analysis of six Cochrane 
reviews, all of which were updated to 2009 (31 random-
ised controlled trials, n = 17,668), conﬁ  rmed that eﬃ   cacy 
is similar among the TNF inhibitors [105]. Adverse 
reactions are thought to be related to TNF blockade, and 
to represent class eﬀ  ects of these agents [106].
In AS, a recent head-to-head, 2-year trial of inﬂ  iximab 
and etanercept in 50 patients with late disease (mean 15.4 
and 15.7 years, respectively) found that adverse events 
were mostly mild to moderate in both groups. Th  ere  were 
no discontinuations for safety reasons and no oppor-
tunistic infections, TB, congestive heart disease, demyeli-
na  ting disorders, lupus-like syndrome or malignancy 
[107]. In an open-label, 5-year (except for a short 
discontinuation at 3 years) randomised controlled trial of 
69 patients with AS who received either inﬂ  iximab or 
placebo, most early adverse events were mild to moder-
ate, except one case of TB and one case of allergic 
bronchio  centric granulomatosis at 1 year [108]. At 3 years 
(n = 43), none of the six SAEs were considered causally 
related to inﬂ  iximab [73]. At 5 years (n = 38) there were 
no safety concerns, and about one-half of the initial 
patient cohort was still being successfully treated [74]. 
Th   ese safety results are consistent with data from a large 
registry [94].
In PsA, the IMPACT 1 and IMPACT 2 studies demon-
strated that inﬂ  iximab was generally well tolerated. In the 
IMPACT 1 study (n = 104), the treatment groups had a 
similar incidence of all adverse events, treatment-related 
adverse events, infusion-related adverse events and both 
SAEs and severe adverse events during the placebo-
controlled phase (weeks 0 to 16) and the crossover phase 
(weeks 16 to 50) [82]. In the IMPACT 2 study (n = 200), 
67 out of 100 inﬂ  iximab patients (67%) experienced an 
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147 out of 173 combined-inﬂ   iximab patients (85%) 
experi  enced an adverse event through week 54 [84]. 
Th  rough week 54, 22 out of 173 patients (12.5%) in the 
combined group also experienced an SAE. Importantly, 
adverse event incidence in the combined-inﬂ  iximab 
group was similar between patients receiving MTX 
(87.5%) and patients not receiving MTX (82.5%) at base-
line. When balanced with the improvement in signs and 
symptoms of PsA, QoL and physical function, and with 
the high degree of ACR and PASI response through 1 
year of inﬂ  iximab treatment, the authors concluded that 
the beneft:risk ratio was positive.
Benefi  t:risk profi  le
Determining the beneﬁ  t:risk  proﬁ   le of TNF inhibitors 
can be challenging, for reasons that include the lack of 
head-to-head clinical trials between drugs and the wide 
variability in the reported rates of SAEs by diﬀ  erent 
studies. Inﬂ   iximab, the drug of focus in the present 
review, has demonstrated eﬃ   cacy in all rheumatological 
conditions (RA, AS and PsA) as well as other inﬂ  amma-
tory disorders (Crohn’s disease, ulcerative colitis and 
psoriasis), and no new or unexpected safety signals have 
arisen over the years. Potential risks exist, but inﬂ  iximab 
is generally well tolerated when clinicians appropriately 
select patients and adhere to indications and contra-
indications. Vigilance regarding important safety con-
sidera  tions continues to be necessary, as is the need for 
adequate patient screening and monitoring.
Few questions remain
Research since 1990 has revealed that an immune-
mediated inﬂ  ammatory mechanism leading to the activa-
tion of proinﬂ  ammatory cytokines underlies RA, AS and 
PsA. Th   is knowledge has driven the development of anti-
TNF agents. Today, TNF inhibitors eﬀ  ectively suppress 
and control the inﬂ  ammation that drives these diseases. 
Suppression and control are critical to the prevention of 
irreversible tissue damage and disability. TNF inhibitors 
have therefore radically changed the entire therapeutic 
approach, which has shifted from mitigation of symptoms 
to blockade of progression.
As with any drug, patient response varies. A proportion 
of patients do not respond, insuﬃ   ciently respond or lose 
an initial good response to classic TNF inhibitors. In such 
patients, other TNF inhibitors, including golimumab 
[109], or other agents, such as the B-cell-depleting 
chimeric antibody rituximab [110-112], the T-cell co-
stimulation inhibitor abatacept [113], or the IL-6 receptor 
inhibitor tocilizumab [114], may be eﬀ  ective.
Studies of the TNF inhibitor inﬂ  iximab  stimulated 
most of the developments recognised today as pertinent 
for TNF inhibitors and also set the stage for other 
biologic agents. Th  e  ﬁ  rst randomised controlled study in 
a rheumatic disease reported the eﬃ   cacy  of  a  single 
infusion of inﬂ  iximab in RA patients 16 years ago [30]. 
Over the 12 years that followed licensing of the ﬁ  rst TNF 
inhibitor for an inﬂ   ammatory disease, research has 
shown that, for most patients, inﬂ  iximab eﬀ  ectively treats 
signs and symptoms, provides rapid and prolonged 
suppression of inﬂ  ammation and may prevent long-term 
disease progression in RA, AS and PsA. In RA, 
inﬂ  iximab, like other TNF blockers, is highly eﬀ  ective for 
both early and established disease, and can induce 
clinical remission. Importantly, initial analysis shows that 
inﬂ  iximab can even maintain remission for approximately 
1 year drug free in patients with early RA. In AS, 
inﬂ  iximab induces a rapid reduction in disease activity; 
and in PsA, inﬂ  iximab treats not only joint symptoms, 
but also extra-articular manifestations, including skin 
disorders, dactylitis, enthesitis and nail disease.
More recently, as we have learned that some patients 
with RA experience RPD despite MTX therapy, an 
aggressive approach early in the disease course has been 
tried. Data are not yet widely available, but subset 
analyses have demonstrated reductions in potential 
markers of RPD (for example, CRP levels, ESR, swollen 
joint count, rheumatoid factor levels) and improved long-
term beneﬁ   ts with the early addition of inﬂ  iximab. 
Inﬂ  iximab has been shown to halt joint destruction even 
in these patients, and predicting RPD may allow tailoring 
of biologic therapy in the disease course.
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